Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia

Therapeutic options for relapsed/refractory B-cell acute lymphoblastic leukemia have evolved in the past few years. The FDA has approved three novel therapies for this disease: inotuzumab ozogamicin (an anti-CD22 antibody–drug conjugate), blinatumomab (a bispecific T-cell engager), and chimeric anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Conde-Royo, Diego, Juárez-Salcedo, Luis Miguel, Dalia, Samir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560100/
https://www.ncbi.nlm.nih.gov/pubmed/33110433
http://dx.doi.org/10.7573/dic.2020-7-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560100/
https://www.ncbi.nlm.nih.gov/pubmed/33110433
http://dx.doi.org/10.7573/dic.2020-7-2

Ejemplares similares